Literature DB >> 16610032

Acute myopathy associated with liver cirrhosis.

Ok-Jae Lee1, Jee-Hyang Yoon, Eun-Jeong Lee, Hyun-Jin Kim, Tae-Hyo Kim.   

Abstract

AIM: Many cirrhotic patients have muscular symptoms and rhabdomyolysis. However, myopathy associated with liver cirrhosis has not been established as a disease entity. We evaluated the clinical significance of acute myopathy associated with liver cirrhosis.
METHODS: We retrospectively reviewed the medical records of 5440 cirrhotic patients who had been admitted to Gyeongsang National University Hospital from August 1997 to January 2003. Among these, 99 developed acute myopathies, and they were analyzed with respect to clinical and laboratory parameters, and outcomes.
RESULTS: The Child-Pugh classification at the time of myopathy onset was A in 3(3.1%) cases, B in 33(33.3%), and C in 63 (63.6%). Infection was identified as the most predisposing factor to myopathy. Fifty percent of 18 idiopathic cases who were tested for influenza antibody were positive. Forty-two of the 99 cases were complicated by acute renal failure, and 25 (59.5%) of these expired. Apart from 6 cases lost to follow-up, 64 of 93 recovered, giving a mortality rate of 31.2%. Mortality was higher in Child-Pugh class C than in B or A.
CONCLUSION: Acute myopathy can develop as a serious complication in liver cirrhosis. Its frequency, severity and mortality depend on underlying liver function, and are higher in decompensated liver cirrhosis. Influenza should be considered as an etiologic factor in idiopathic cases. It is proposed that acute myopathy associated with liver cirrhosis be called 'hepatic myopathy', and that careful monitoring for hepatic myopathy is necessary in the patients with advanced liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16610032      PMCID: PMC4087657          DOI: 10.3748/wjg.v12.i14.2254

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  SERUM CREATINE PHOSPHOKINASE (CPK) ACTIVITY IN DISORDERS OF HEART AND SKELETAL MUSCLE.

Authors:  J W HESS; R P MACDONALD; R J FREDERICK; R N JONES; J NEELY; D GROSS
Journal:  Ann Intern Med       Date:  1964-12       Impact factor: 25.391

2.  Acute myoglobinuria; report of a case with fatal outcome.

Authors:  R HED; H LARSSON; F WAHLGREN
Journal:  Acta Med Scand       Date:  1955-12-07

3.  Massive rhabdomyolysis: a rare presentation of primary Vibrio vulnificus septicemia.

Authors:  A Fernandez; F R Justiniani
Journal:  Am J Med       Date:  1990-10       Impact factor: 4.965

4.  Influenza A and rhabdomyolysis.

Authors:  W Foulkes; J Rees; C Sewry
Journal:  J Infect       Date:  1990-11       Impact factor: 6.072

5.  Painful muscle cramps. A symptom of liver cirrhosis?

Authors:  F Konikoff; E Theodor
Journal:  J Clin Gastroenterol       Date:  1986-12       Impact factor: 3.062

6.  Alcoholic muscle disease.

Authors:  F C Martin; G Slavin; A J Levi
Journal:  Br Med Bull       Date:  1982-01       Impact factor: 4.291

7.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.

Authors:  P Sort; M Navasa; V Arroyo; X Aldeguer; R Planas; L Ruiz-del-Arbol; L Castells; V Vargas; G Soriano; M Guevara; P Ginès; J Rodés
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

8.  Alcoholic muscle disease.

Authors:  F Martin; T J Peters
Journal:  Alcohol Alcohol       Date:  1985       Impact factor: 2.826

9.  Alcoholic skeletal myopathy, a clinical and pathological study.

Authors:  F Martin; K Ward; G Slavin; J Levi; T J Peters
Journal:  Q J Med       Date:  1985-06

Review 10.  Acute renal failure complicating muscle crush injury.

Authors:  Z A Abassi; A Hoffman; O S Better
Journal:  Semin Nephrol       Date:  1998-09       Impact factor: 5.299

View more
  2 in total

1.  Apparent Diffusion Coefficient Is a Novel Imaging Biomarker of Myopathic Changes in Liver Cirrhosis.

Authors:  Alexey Surov; Lisa Paul; Hans Jonas Meyer; Stefan Schob; Cornelius Engelmann; Andreas Wienke
Journal:  J Clin Med       Date:  2018-10-15       Impact factor: 4.241

2.  Regulation of MYO18B mRNA by a network of C19MC miRNA-520G, IFN-γ, CEBPB, p53 and bFGF in hepatocellular carcinoma.

Authors:  Goodwin G Jinesh; Marco Napoli; Hayley D Ackerman; Payal M Raulji; Nicole Montey; Elsa R Flores; Andrew S Brohl
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.